Transjugular Intrahepatic Portosystemic Shunt Placement: Effects on Nutritional Status in Cirrhotic Patients

Overview

Journal J Clin Med

Specialty General Medicine

Date 2023 Nov 25

PMID 38002642

Authors

Ilaria de Felice

Lorenzo Ridola

Oliviero Riggio

Jessica Faccioli

Silvia Nardelli

Stefania Gioia

Affiliations

Soon will be listed here.

Abstract

Malnutrition is a tangible complication of cirrhosis with portal hypertension with a prevalence of up to 50%. In particular, sarcopenia and myosteatosis, defined as the alteration in muscle quantity and quality, have a negative impact on the main complications of liver disease and are associated with higher mortality in patients with cirrhosis. Recently, alterations in adipose tissue have also been described in cirrhotic patients and they seem to influence the course of liver disease. Several pieces of evidence indicate that a transjugular intrahepatic portosystemic shunt (TIPS), placed for the treatment of refractory portal hypertension, can lead to a modification of body composition consisting in the improvement of the skeletal muscle index, myosteatosis, and an increase in subcutaneous fat. These modifications of the nutritional status, even more pronounced in sarcopenic patients before TIPS, have been associated with an amelioration of cognitive impairment after TIPS as well as with an increase in the survival rate. The aim of this paper is to provide an overview of the effects of TIPS placement on nutritional status in cirrhosis focusing on its pathophysiological mechanisms and its relationship with liver-related outcomes.

References

Pang N, Zhao C, Li J, Li L, Yang X, Yang M . Body mass index changes after transjugular intrahepatic portosystemic shunt in individuals with cirrhosis. Nutrition. 2021; 84:111095. DOI: 10.1016/j.nut.2020.111095. View

Gioia S, Ridola L, Cristofaro L, Merli M, Faccioli J, Riggio O . The improvement in body composition including subcutaneous and visceral fat reduces ammonia and hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Liver Int. 2021; 41(12):2965-2973. PMC: 9293456. DOI: 10.1111/liv.15060. View

Stanley A, Gilmour H, Ghosh S, Ferguson A, McGilchrist A . Transjugular intrahepatic portosystemic shunt as a treatment for protein-losing enteropathy caused by portal hypertension. Gastroenterology. 1996; 111(6):1679-82. DOI: 10.1016/s0016-5085(96)70033-1. View

Marchesini G, Bianchi G, Merli M, Amodio P, Panella C, Loguercio C . Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology. 2003; 124(7):1792-801. DOI: 10.1016/s0016-5085(03)00323-8. View

Ronald J, Bozdogan E, Zaki I, Kappus M, Choi S, Martin J . Relative Sarcopenia With Excess Adiposity Predicts Survival After Transjugular Intrahepatic Portosystemic Shunt Creation. AJR Am J Roentgenol. 2019; 214(1):200-205. DOI: 10.2214/AJR.19.21655. View

Hey P, Chapman B, Wong D, Gow P, Testro A, Terbah R . Transjugular intrahepatic portosystemic shunt insertion improves muscle mass but not muscle function or frailty measures. Eur J Gastroenterol Hepatol. 2023; 35(9):997-1003. DOI: 10.1097/MEG.0000000000002592. View

Alatzides G, Haubold J, Steinberg H, Koitka S, Parmar V, Grueneisen J . Adipopenia in body composition analysis: a promising imaging biomarker and potential predictive factor for patients undergoing transjugular intrahepatic portosystemic shunt placement. Br J Radiol. 2023; 96(1146):20220863. PMC: 10230376. DOI: 10.1259/bjr.20220863. View

Tsien C, McCullough A, Dasarathy S . Late evening snack: exploiting a period of anabolic opportunity in cirrhosis. J Gastroenterol Hepatol. 2011; 27(3):430-41. DOI: 10.1111/j.1440-1746.2011.06951.x. View

Wang X, Sun M, Li Y, Guo G, Yang W, Mao L . Association of myosteatosis with various body composition abnormalities and longer length of hospitalization in patients with decompensated cirrhosis. Front Nutr. 2022; 9:921181. PMC: 9520990. DOI: 10.3389/fnut.2022.921181. View

10.

Plauth M, Schutz T, Buckendahl D, Kreymann G, Pirlich M, Grungreiff S . Weight gain after transjugular intrahepatic portosystemic shunt is associated with improvement in body composition in malnourished patients with cirrhosis and hypermetabolism. J Hepatol. 2004; 40(2):228-33. DOI: 10.1016/j.jhep.2003.10.011. View

11.

Lattanzi B, Gioia S, Di Cola S, DAmbrosio D, Nardelli S, Tavano D . Prevalence and impact of sarcopenia in non-cirrhotic portal hypertension. Liver Int. 2019; 39(10):1937-1942. DOI: 10.1111/liv.14160. View

12.

Allaire M, Walter A, Sutter O, Nahon P, Ganne-Carrie N, Amathieu R . TIPS for management of portal-hypertension-related complications in patients with cirrhosis. Clin Res Hepatol Gastroenterol. 2019; 44(3):249-263. DOI: 10.1016/j.clinre.2019.09.003. View

13.

Montomoli J, Holland-Fischer P, Bianchi G, Gronbaek H, Vilstrup H, Marchesini G . Body composition changes after transjugular intrahepatic portosystemic shunt in patients with cirrhosis. World J Gastroenterol. 2010; 16(3):348-53. PMC: 2807956. DOI: 10.3748/wjg.v16.i3.348. View

14.

Gazda J, Di Cola S, Lapenna L, Khan S, Merli M . The Impact of Transjugular Intrahepatic Portosystemic Shunt on Nutrition in Liver Cirrhosis Patients: A Systematic Review. Nutrients. 2023; 15(7). PMC: 10096634. DOI: 10.3390/nu15071617. View

15.

Bhanji R, Moctezuma-Velazquez C, Duarte-Rojo A, Ebadi M, Ghosh S, Rose C . Myosteatosis and sarcopenia are associated with hepatic encephalopathy in patients with cirrhosis. Hepatol Int. 2018; 12(4):377-386. DOI: 10.1007/s12072-018-9875-9. View

16.

Nardelli S, Lattanzi B, Torrisi S, Greco F, Farcomeni A, Gioia S . Sarcopenia Is Risk Factor for Development of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt Placement. Clin Gastroenterol Hepatol. 2016; 15(6):934-936. DOI: 10.1016/j.cgh.2016.10.028. View

17.

De Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C . Baveno VII - Renewing consensus in portal hypertension. J Hepatol. 2022; 76(4):959-974. PMC: 11090185. DOI: 10.1016/j.jhep.2021.12.022. View

18.

Kalafateli M, Karatzas A, Tsiaoussis G, Koutroumpakis E, Tselekouni P, Koukias N . Muscle fat infiltration assessed by total psoas density on computed tomography predicts mortality in cirrhosis. Ann Gastroenterol. 2018; 31(4):491-498. PMC: 6033770. DOI: 10.20524/aog.2018.0256. View

19.

Nardelli S, Bellafante D, Ridola L, Faccioli J, Riggio O, Gioia S . Prevention of post-tips hepatic encephalopathy: The search of the ideal candidate. Metab Brain Dis. 2022; 38(5):1729-1736. DOI: 10.1007/s11011-022-01131-0. View

20.

Lai J, Tandon P, Bernal W, Tapper E, Ekong U, Dasarathy S . Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021; 74(3):1611-1644. PMC: 9134787. DOI: 10.1002/hep.32049. View